Featured
-
-
-
In Brief |
Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
- Jordan Hindson
-
-
-
Review Article |
Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Hepatic stellate cells (HSCs) drive liver fibrosis and are closely linked to liver cancer development. This comprehensive Review provides an in-depth analysis of the specific characteristics of HSCs in cancer, highlighting therapeutic implications based on progress in clarifying HSC biology.
- Bruno Cogliati
- , Chittampalli N. Yashaswini
- & Scott L. Friedman
-
Review Article |
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
In this Review, Huang et al. discuss the current status of hepatocellular carcinoma surveillance, the remaining challenges, including the changing aetiology of liver disease, and strategies to improve the utilization and quality of surveillance.
- Daniel Q. Huang
- , Amit G. Singal
- & Rohit Loomba
-
-
Review Article |
Evolving therapeutic landscape of advanced hepatocellular carcinoma
This Review discusses the current and emerging therapeutic landscape for treatment of advanced hepatocellular carcinoma, including molecular-targeted monotherapies, immuno-oncology monotherapies, combination therapies and novel therapeutic approaches.
- Chen Yang
- , Hailin Zhang
- & Cun Wang
-
Review Article |
Benign liver tumours: understanding molecular physiology to adapt clinical management
Here, the authors provide an overview of benign liver tumours (hepatic haemangioma, focal nodular hyperplasia and hepatocellular adenoma), including pathogenesis, diagnosis and management. Insights into how molecular physiology could inform clinical practice are also highlighted.
- Jean-Charles Nault
- , Valérie Paradis
- & Jessica Zucman-Rossi
-
Review Article |
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
Surveillance of hepatocellular carcinoma (HCC), one of the most lethal solid cancers globally, is insensitive for the detection of early-stage tumours. In this Review, the authors discuss HCC biomarkers that can improve early diagnosis, therapy monitoring and prediction of therapy response.
- Philip Johnson
- , Qing Zhou
- & Y. M. Dennis Lo
-
-
-
-
Review Article |
Neutrophils as potential therapeutic targets in hepatocellular carcinoma
Growing evidence indicates that neutrophils are involved in tumorigenesis, progression and metastasis of hepatocellular carcinoma (HCC). Here, Geh and colleagues summarize neutrophil phenotypes in HCC, describe the pathogenetic mechanisms underlying these contributions of neutrophils to HCC and highlight emerging neutrophil-targeted therapies.
- Daniel Geh
- , Jack Leslie
- & Derek A. Mann
-
-
Review Article |
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
The complexity of hepatocellular carcinoma (HCC) hinders effective treatment. Here, Lee and colleagues summarize cancer stem cell (CSC) origin and plasticity, CSC–immune system interactions and the effects of the microenvironmental niche on cancer stemness in HCC. Potential CSC-based therapies for HCC are also presented.
- Terence Kin-Wah Lee
- , Xin-Yuan Guan
- & Stephanie Ma
-
-
-
-
-
Review Article |
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Farnesoid X receptor (FXR) is involved in the control of bile acid synthesis and enterohepatic circulation. This Review discusses the role of FXR in metabolic diseases and gastrointestinal and liver cancers, highlighting underlying mechanisms and potential therapeutic targets.
- Lulu Sun
- , Jie Cai
- & Frank J. Gonzalez
-
Review Article |
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Locoregional therapies, defined as imaging-guided liver tumour-directed procedures, play a leading part in the management of hepatocellular carcinoma. This Review analyses data from randomized and uncontrolled studies reported with ablative and locoregional techniques and examines the expected effects of combinations with systemic treatments, exploring their distinct mechanisms of action.
- Josep M. Llovet
- , Thierry De Baere
- & Riccardo Lencioni
-
Review Article |
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
The prevalence of nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) is projected to continue to increase worldwide. In this Review, Huang, El-Serag and Loomba discuss the global epidemiology and risk factors for NAFLD-related HCC, and propose strategies to tackle this problem.
- Daniel Q. Huang
- , Hashem B. El-Serag
- & Rohit Loomba
-
Review Article |
Maladaptive regeneration — the reawakening of developmental pathways in NASH and fibrosis
Emerging data have revealed that nonalcoholic steatohepatitis (NASH) and fibrosis are associated with the reactivation of developmental pathways in the liver injury response. This Review describes the role of these pathways in liver development and in the pathogenesis of NASH and fibrosis.
- Changyu Zhu
- , Ira Tabas
- & Utpal B. Pajvani
-
-
-
-
Review Article |
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Several big data ‘omics’ studies have analysed hepatocellular carcinoma (HCC). This Review describes omics studies in HCC and their potential in drug discovery and as candidate biomarkers. The application of emerging new artificial intelligence methods in HCC drug discovery is also discussed.
- Bin Chen
- , Lana Garmire
- & Xin Chen
-
Review Article |
Tumour evolution in hepatocellular carcinoma
This Review discusses the molecular heterogeneity of hepatocellular carcinoma, the intrinsic and extrinsic factors that stimulate tumour evolution and how this information can be leveraged to improve the clinical management of patients with this disease.
- Amanda J. Craig
- , Johann von Felden
- & Augusto Villanueva
-
Year in Review |
What’s new in NAFLD pathogenesis, biomarkers and treatment?
Advances have been made in the field of nonalcoholic fatty liver disease in 2019. One paper highlights the role of gut microbiota in hepatocellular carcinoma (HCC) pathogenesis, another presents a noninvasive algorithm for detecting advanced liver fibrosis and another suggests a potential novel approach to treating nonalcoholic steatohepatitis and suppressing HCC development.
- Christopher D. Byrne
- & Giovanni Targher
-
Review Article |
Metabolic rearrangements in primary liver cancers: cause and consequences
Primary liver cancers are frequently accompanied by rearrangements of metabolic pathways. This Review discusses the role of metabolic liver disruptions and the implications of these processes, emphasizing their clinical relevance and value in early diagnosis and prognosis and as putative therapeutic targets.
- Letizia Satriano
- , Monika Lewinska
- & Jesper B. Andersen
-
Review Article |
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. This Review summarizes the epidemiology, risk factors (including viral hepatitis and NAFLD), molecular profiles and treatment of HCC, providing insights into how the global burden of HCC can be reduced.
- Ju Dong Yang
- , Pierre Hainaut
- & Lewis R. Roberts
-
-
Research Highlight |
Mapping the cells in the liver — unchartered subtypes and heterogeneity
- Katrina Ray
-
-
-
-
News & Views |
Sensitizing hepatocellular carcinoma to oncolytic virus therapy
Oncolytic viruses have made headlines owing to increasing numbers of reports of clinical success. Compelling data now indicate that small anticancer molecules can serve as potent sensitizers of tumour cells in hepatocellular carcinoma to enhance the oncolytic potential of systemically applied viruses.
- Jennifer Altomonte
-
Review Article |
Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Bile acids link the gut microbiota to both hepatic and intestinal metabolism, and this tripartite relationship has been implicated in gastrointestinal disease. In this Review, the authors outline the mechanistic links between bile acid–microbiota crosstalk and gastrointestinal inflammation and carcinogenesis, with a specific emphasis on the major bile-acid-sensing receptors.
- Wei Jia
- , Guoxiang Xie
- & Weiping Jia
-
-
-
-
Review Article |
Immunological landscape and immunotherapy of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is an antigenic lesion infiltrated by T cells, but factors within the tumour and its microenvironment dampen the immune response and prevent effective antitumour immunity. The stepwise elucidation of the various immunosuppressive mechanisms at play in HCC has exposed new therapeutic options. This Review gives a comprehensive overview of the different immunotherapeutic modalities applicable in HCC, including vaccines, adoptive T-cell therapy, cytokines, gene therapy and immune checkpoint inhibitors.
- Jesús Prieto
- , Ignacio Melero
- & Bruno Sangro